Company: EDSA
Filing Date: 2025-05-14
Form Type: 10-Q
Source: 0001171843-25-003189
Chunk: 30

Company: Edesa Biotech, Inc.
Filing Date: 2025-05-14
Form: 10-Q
Item: Part I, Item 8
Chunk 30
---
 43,031

			 43,031

			$
			
			22.12

			Feb 2030

			 51,006

			 51,006

			$
			
			52.08 - 56.49 

			September 2030 - Oct 2030

			 81,041

			 81,041

			$
			
			36.75 - 40.18 

			March 2025 - Sep 2031

			 58,753

			 57,304

			$
			
			25.97

			March 2025 - Feb 2032

			 111,116

			 70,025

			$
			
			4.10 - 10.01 

			March 2025 - Oct 2033

			 382,666

			 340,126

The options exercisable at March 31, 2025 had a weighted average exercise price of $24.66, no intrinsic value and a weighted average remaining life of 72 months. There were 33,354 options at March 31, 2025 that had not vested with a weighted average exercise price of $7.12, no intrinsic value and a weighted average remaining life of 98 months.

13

The fair value of options granted during the six months ended March 31, 2025 and 2024 was estimated using the Black-Scholes option valuation model using the following assumptions:

			Six Months Ended March 31, 2024

			Risk free interest rate

			4.92
			%

			Expected life

			5 years

			Expected share price volatility

			97.26
			%

			Expected dividend yield

			0.00
			%

The Company recorded $0.1 million and $0.1 million of share-based compensation expenses for the three months ended March 31, 2025 and 2024, respectively and $0.1 million and $0.3 million for the six months ended March 31, 2025 and 2024, respectively.

As of March 31, 2025, the Company had approximately $0.1 million of unrecognized share-based compensation expense, which is expected to be recognized over a period of 18 months.

Restricted share units (RSU)

The Company’s 201